Primary lung cancer cell culture from transthoracic needle biopsy samples

Herreño, Angélica María; Fernández, M; Rey, Laura; Mejía, Juan; Cañas, Alejandra; Moreno, Olga; Henríquez, Berta; Montecino, Martín; Rojas, Alejandra

doi:10.1080/2331205x.2018.1503071

Cited by 6 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary cell culture was established from biopsies following our protocol from previous research. 24 From these samples, gene expression and chromatin immunoprecipitation (ChIP) analyses were performed.…”

Section: Methodsmentioning

confidence: 99%

Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer: Epigenetic control of the RUNX2 P1 promoter

et al. 2019

Self Cite

View full text Add to dashboard Cite

Lung cancer has a high mortality rate in men and women worldwide. Approximately 15% of diagnosed patients with this type of cancer do not exceed the 5-year survival rate. Unfortunately, diagnosis is established in advanced stages, where other tissues or organs can be affected. In recent years, lineage-specific transcription factors have been associated with a variety of cancers. One such transcription factor possibly regulating cancer is RUNX2, the master gene of early and late osteogenesis. In thyroid and prostate cancer, it has been reported that RUNX2 regulates expression of genes important in tumor cell migration and invasion. In this study, we report on RUNX2/ p57 overexpression in 16 patients with primary non-small cell lung cancer and/or metastatic lung cancer associated with H3K27Ac at P1 gene promoter region. In some patients, H3K4Me3 enrichment was also detected, in addition to WDR5, MLL2, MLL4, and UTX enzyme recruitment, members of the COMPASS-LIKE complex. Moreover, transforming growth factor-β induced RUNX2/ p57 overexpression and specific RUNX2 knockdown supported a role for RUNX2 in epithelial mesenchymal transition, which was demonstrated through loss of function assays in adenocarcinoma A549 lung cancer cell line. Furthermore, RUNX2 increased expression of epithelial mesenchymal transition genes VIMENTIN, TWIST1, and SNAIL1, which reflected increased migratory capacity in lung adenocarcinoma cells.

show abstract

Section: Methodsmentioning

confidence: 99%

Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer: Epigenetic control of the RUNX2 P1 promoter

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…no. A3840201; Gibco; Thermo Fisher Scientific, Inc.) in a sterile 24-well culture plate (18). using a stereoscope, solid tumors were fractionated mechanically with scissors or a scalpel.…”

Section: Methodsmentioning

confidence: 99%

“…no. 2520056; Gibco; Thermo Fisher Scientific, Inc.), and then the passages were transferred to Petri dishes of 35, 60 and 100 mm (18). Once 100% confluency was reached, the cells were used for immunohistochemistry, gene expression, cytogenetic and epigenetic analysis.…”

Section: Methodsmentioning

confidence: 99%

Epigenetic control of the EWS‑FLI1 promoter in Ewing's sarcoma

et al. 2020

View full text Add to dashboard Cite

Ewing sarcoma (ES) is a primary bone marrow tumor that very rarely develops in extra-osseous tissues, such as lung. The hallmark of ES tumors is a translocation between chromosomes 11 and 22, resulting in a fusion protein, commonly referred to as EWS-FLI1. The epigenetic profile (histone acetylation and methylation enrichment of the promoter region) that may regulate the expression of the aberrant transcription factor EWS-FLI1, remains poorly studied and understood. Knowledge of epigenetic patterns associated with covalent histone modification and expression of enzymes associated with this process, can contribute to the understanding of the molecular basis of the disease, as well as to the identification of possible molecular targets involved in expression of the EWS-FLI1 gene, so that therapeutic strategies may be improved in the future. In the present study, the transcriptional activation and repression of the EWS-FLI1 fusion gene in ES was accompanied by selective deposition of histone markers on its promoter. The EWS-FLI1 fusion gene was evaluated in two patients with ES using conventional cytogenetic, fluorescence in situ hybridization and nested PCR assays, which revealed that the aberrant expression of the EWS-FLI1 gene is accompanied by enrichment of H3K4Me3, H3K9ac and H3K27ac at the promoter region.

show abstract

“…Generally, primary cell cultures retain the morphological and biochemical characteristics of the tumor from which they were originally derived [ 84 ]. The primary cell culture highly represents the native epithelia, as they are isolated directly from the tissue, thus having more similarity in the cell characteristics.…”

Section: Cellular Evaluation Of Drug Delivery System For Lung Cancermentioning

confidence: 99%

“…Both cell models are cultured to form multi-layered, well-differentiated models that closely resemble the respiratory tracts’ epithelial tissues. Results have shown that primary lung cancer cell culture is possible to be obtained from percutaneous puncture, providing a significant biological source to assess and investigate lung cancer’s molecular mechanisms [ 84 ]. Furthermore, primary cultures preserve cancer cells with stem-like phenotypes, an advantage not always offered by cell lines.…”

Section: Cellular Evaluation Of Drug Delivery System For Lung Cancermentioning

confidence: 99%

Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment

Mohtar

Parumasivam

Gazzali

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancers, the number one cancer killer, can be broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being the most commonly diagnosed type. Anticancer agents for NSCLC suffer from various limitations that can be partly overcome by the application of nanomedicines. Nanoparticles is a branch within nanomedicine that can improve the delivery of anticancer drugs, whilst ensuring the stability and sufficient bioavailability following administration. There are many publications available in the literature exploring different types of nanoparticles from different materials. The effectiveness of a treatment option needs to be validated in suitable in vitro and/or in vivo models. This includes the developed nanoparticles, to prove their safety and efficacy. Many researchers have turned towards in vitro models that use normal cells or specific cells from diseased tissues. However, in cellular works, the physiological dynamics that is available in the body could not be mimicked entirely, and hence, there is still possible development of false positive or false negative results from the in vitro models. This article provides an overview of NSCLC, the different nanoparticles available to date, and in vitro evaluation of the nanoparticles. Different types of cells suitable for in vitro study and the important precautions to limit the development of false results are also extensively discussed.

show abstract

Primary lung cancer cell culture from transthoracic needle biopsy samples

Cited by 6 publications

References 37 publications

Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer: Epigenetic control of the RUNX2 P1 promoter

Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer: Epigenetic control of the RUNX2 P1 promoter

Epigenetic control of the EWS‑FLI1 promoter in Ewing's sarcoma

Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment

Contact Info

Product

Resources

About